How many drugs treat Edema due to Hepatic Cirrhosis?

Drug Landscape tracks 8 marketed treatments for Edema due to Hepatic Cirrhosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/edema-due-to-hepatic-cirrhosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Edema due to Hepatic Cirrhosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Edema due to Hepatic Cirrhosis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Edema due to Hepatic Cirrhosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lasix	furosemide	Generic (originally Hoechst AG)	Loop Diuretic [EPC]	ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35	1966-07-01
Aldactone	spironolactone	Generic (originally Searle/Pfizer)	Aldosterone Antagonist [EPC]	Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2	1960-01-01
Microzide	hydrochlorothiazide	Generic (originally Merck)	Thiazide Diuretic [EPC]	ACE	1959-01-01
Diuril	CHLOROTHIAZIDE	Salix Pharms	Thiazide Diuretic	Solute carrier family 12 member 3	1958-01-01
Spironolacton	Spironolacton	ACS Biomarker		Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2
Frusemide	Frusemide	Melbourne Health		ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35
Torasemide	Torasemide	Medical University of Warsaw		Solute carrier family 12 member 1
spirolactone	spirolactone	Second Xiangya Hospital of Central South University		Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Edema due to Hepatic Cirrhosis
ACS Biomarker · 1 drug in Edema due to Hepatic Cirrhosis
Generic (originally Hoechst AG) · 1 drug in Edema due to Hepatic Cirrhosis
Generic (originally Merck) · 1 drug in Edema due to Hepatic Cirrhosis
Generic (originally Searle/Pfizer) · 1 drug in Edema due to Hepatic Cirrhosis
Medical University of Warsaw · 1 drug in Edema due to Hepatic Cirrhosis
Melbourne Health · 1 drug in Edema due to Hepatic Cirrhosis
Salix Pharms · 1 drug in Edema due to Hepatic Cirrhosis
Second Xiangya Hospital of Central South University · 1 drug in Edema due to Hepatic Cirrhosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Edema due to Hepatic Cirrhosis:

Cite this brief

Drug Landscape (2026). Edema due to Hepatic Cirrhosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/edema-due-to-hepatic-cirrhosis. Accessed 2026-06-10.

Edema due to Hepatic Cirrhosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing